Wed, Oct 22, 2014, 10:36 AM EDT - U.S. Markets close in 5 hrs 24 mins

Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

  • amlnlover100 amlnlover100 Jan 20, 2013 9:21 AM Flag

    ST-148 a potent inhibitor of all four serotypes of DENV in vitro.

    We saw this in pre-publication, but it is now out. The number of authors hints they believe it’s an important paper. Looking good, albeit early work. But note, there is nothing here barring them from having more, but holding back more advanced stuff.

    A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein
    Chelsea M. Byrda, Dongcheng Daia, Douglas W. Grosenbacha, Aklile Berhanua, Kevin F. Jonesa, Kara B. Cardwella, Christine Schneidera, Kristin A. Wineingera, Jessica M. Pagea, Chris Harvera, Eric Stavalea, Shanthakumar Tyavanagimatta, Melialani A. Stonea, Ralf Bartenschlagerb, Pietro Scaturrob, Dennis E. Hrubya and Robert Jordana

    Antimicrob. Agents Chemother. January 2013 vol. 57 no. 1 15-25

    Author Affiliations
    SIGA Technologies, Inc., Corvallis, Oregon, USA
    Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany

    ABSTRACT
    Dengue viruses (DENV) infect 50 to 100 million people worldwide per year, of which 500,000 develop severe life-threatening disease. This mosquito-borne illness is endemic in most tropical and subtropical countries and has spread significantly over the last decade. While there are several promising vaccine candidates in clinical trials, there are currently no approved vaccines or therapeutics available for treatment of dengue infection. Here, we describe a novel small-molecule compound, ST-148, that is a potent inhibitor of all four serotypes of DENV in vitro. ST-148 significantly reduced viremia and viral load in vital organs and tended to lower cytokine levels in the plasma in a nonlethal model of DENV infection in AG129 mice. Compound resistance mapped to the DENV capsid (C) gene, and a direct interaction of ST-148 with C protein is suggested by alterations of the intrinsic fluorescence of the protein in the presence of compound. Thus, ST-148 appears to interact with the DENV C protein and inhibits a distinct step(s) of the viral replication cycle.

    FOOTNOTES
    Received 11 July 2012
    Returned for modification 3 August 2012
    Accepted 26 September 2012
    Published ahead of print 15 October 2012

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SIGA
1.45-0.01(-0.68%)10:36 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.